188 related articles for article (PubMed ID: 24771049)
1. Prognostic factors for survival in metastatic breast cancer by hormone receptor status.
Kwast AB; Voogd AC; Menke-Pluijmers MB; Linn SC; Sonke GS; Kiemeney LA; Siesling S
Breast Cancer Res Treat; 2014 Jun; 145(2):503-11. PubMed ID: 24771049
[TBL] [Abstract][Full Text] [Related]
2. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer.
Chen S; Chen CM; Yu KD; Zhou RJ; Shao ZM
Ann Surg Oncol; 2012 Sep; 19(9):3002-11. PubMed ID: 22437200
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer.
Livi L; Meattini I; Saieva C; Franzese C; Di Cataldo V; Greto D; Franceschini D; Scotti V; Bonomo P; Nori J; Sanchez L; Vezzosi V; Bianchi S; Cataliotti L; Biti G
Cancer; 2012 Jul; 118(13):3236-43. PubMed ID: 22028054
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
9. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
[TBL] [Abstract][Full Text] [Related]
10. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
Clin Breast Cancer; 2017 Aug; 17(5):356-366. PubMed ID: 28576631
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of HER2 status and efficacy of anti-HER2 therapy in patients with HR-positive mucinous breast cancer: a nationwide study from the Korean Breast Cancer Society.
Kim HS; Yoo TK; Park WC; Chae BJ
Breast Cancer Res Treat; 2020 Apr; 180(2):461-470. PubMed ID: 32020434
[TBL] [Abstract][Full Text] [Related]
12. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
14. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
15. A 10-year follow-up of triple-negative breast cancer patients in Taiwan.
Lin C; Chien SY; Kuo SJ; Chen LS; Chen ST; Lai HW; Chang TW; Chen DR
Jpn J Clin Oncol; 2012 Mar; 42(3):161-7. PubMed ID: 22287721
[TBL] [Abstract][Full Text] [Related]
16. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
Todorovic-Rakovic N; Neskovic-Konstantinovic Z
J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
[TBL] [Abstract][Full Text] [Related]
17. Is conservative surgery a good option for patients with "triple negative" breast cancer?
Martinez-Ramos D; Escrig-Sos J; Torrella-Ramos A; Alcalde-Sanchez M; Salvador-Sanchis JL
Breast; 2012 Jun; 21(3):401-5. PubMed ID: 22579462
[TBL] [Abstract][Full Text] [Related]
18. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN
Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of MARCKS-like 1 in lymph node-negative breast cancer.
Jonsdottir K; Zhang H; Jhagroe D; Skaland I; Slewa A; Björkblom B; Coffey ET; Gudlaugsson E; Smaaland R; Janssen EA; Baak JP
Breast Cancer Res Treat; 2012 Sep; 135(2):381-90. PubMed ID: 22772381
[TBL] [Abstract][Full Text] [Related]
20. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.
Liu YR; Jiang YZ; Yu KD; Shao ZM
Ann Surg Oncol; 2015 Apr; 22(4):1102-10. PubMed ID: 25249260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]